Sigilon Therapeutics approaches the clinic
Orphan status for its haemophilia cell therapy and buy-in from Lilly on its diabetes project are good signs for Sigilon, but research is still very early.
With new unicorn status, CMR Surgical sets profitability target
CMR Surgical’s private round is the largest ever venture deal for a European medtech. And the point is to get to profitability, not flotation.
Nuvaira hopes to go with the flow in COPD
If its study of lung denervation hits, Nuvaira could get US approval and maybe swing a trade sale.
Digital therapeutics have potential but commercial success unproven
Software can be a medical device. Can it also be a drug?
Ablative Solutions has a fight on its hands in renal denervation
Alcohol kills – and in this case, that could be a good thing.
Vizai hopes Medtronic deal will boost sales of its tech – and vice versa
Medtronic decides that Solitaire is best played with a partner.
Probiodrug changes its name but remembers its roots
Probiodrug changes its name to Vivoryon and expands its focus to include oncology, but insists that it is still first and foremost an Alzheimer’s company.
Emmaus tries to move forwards by reversing
The company insists that its sickle cell disease therapy Endari still has a future, despite questionable efficacy and the approach of new treatments.
Liquid biopsies: the future of cancer diagnosis?
Blood tests could be faster and cheaper than tissue biopsies, but a Thermo Fisher exec argues they are likely to be more of an add-on technique.
